Clinuvel Pharmaceuticals
Clinuvel Pharmaceuticals Ltd is an Australian biopharmaceutical company developing afamelanotide, a first in class photoprotective drug. Headquartered in Melbourne, with offices in San Francisco and Zürich, Clinuvel's focus is to gain market approval for afamelanotide in the prophylactic treatment of UV and light related skin disorders. Click to enter corporate.clinuvel.com Since its inception 13 years ago, Clinuvel has developed significant knowledge focused on skin, light and UV and melanin. Clinuvel Photoprotection shares this knowledge on three levels – general, professional and academic – and provides access to experts and thought leaders from around the world. Click to enter photoprotection.clinuvel.com

Direct links:

Direct links:
About Clinuvel Company Reports Dermatology Xptise Discussions
Company objectives Latest report Dermatology Thought Leader discussions
About afamelanotide Reports archive Skin conditions Dermatology discussions
Share Price Announcements Light & Melanin Xptise Q&As
Australian share price Company annoncements Light & UV Ask a professional
Foreign share prices Media coverage Melanin Browse questions
Melbourne | Zürich | San Francisco